Exicure stock surges after completing Phase 2 trial enrollment

Published 01/08/2025, 21:08
© Reuters.

Investing.com -- Exicure Inc (NASDAQ:XCUR) stock jumped 25% after the clinical-stage biotechnology company announced it has completed the last patient visit in its Phase 2 clinical trial of GPC-100 for multiple myeloma patients undergoing stem cell transplant.

The company expects to release topline results from the study in the fourth quarter of 2025. The trial is evaluating whether GPC-100, a small molecule CXCR4 antagonist, can improve the mobilization of hematopoietic stem cells from bone marrow into peripheral blood for collection and use in autologous stem cell transplant procedures.

According to data presented at ASH 2024, GPC-100 appears to differentiate itself from current treatments by the speed at which it mobilizes stem cells. The drug requires administration just 45 minutes before stem cell collection, potentially offering logistical advantages over traditional mobilization methods.

Dr. Muthalagu Ramanathan, Director of the Myeloma Program at U Mass Memorial Health, highlighted the potential benefit for patients, noting that traditional mobilization methods require patients to receive injections the night before procedures, adding logistical challenges.

Beyond multiple myeloma, Exicure is planning a Phase 1 study in acute myeloid leukemia patients and is exploring potential collaborations that would leverage GPC-100’s capabilities in cell and gene therapy applications.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.